Patents Assigned to Hythiam, Inc.
-
Patent number: 7863267Abstract: The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and/or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and/or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.Type: GrantFiled: May 13, 2008Date of Patent: January 4, 2011Assignee: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez
-
Publication number: 20090215751Abstract: The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and/or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and/or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.Type: ApplicationFiled: March 13, 2009Publication date: August 27, 2009Applicant: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez
-
Publication number: 20080280885Abstract: The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, methods of, and compositions for, modulating the expression of certain GABAA receptor subunits are used to treat anxiety-related disorders and depressive disorders associated with physiological tolerance to endogenous neurosteroids.Type: ApplicationFiled: April 7, 2006Publication date: November 13, 2008Applicant: Hythiam, INC.Inventors: Sanjay Sabnani, Donald Wesson
-
Publication number: 20080255097Abstract: The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. More specifically, the present invention relates to methods of and compositions for treating and relieving symptoms associated with substance abuse and withdrawal. The present invention relates to methods of and compositions for treating and relieving symptoms associated with addiction to antidepressants, opiates, nicotine or marijuana. In one method, a patient is treated with a composition that directly or indirectly modulates GABAA by modulating the expression of the GABAA receptor a4 subunit.Type: ApplicationFiled: April 7, 2006Publication date: October 16, 2008Applicant: Hythiam, Inc.Inventors: Sanjay Sabnani, Donald Wesson, Joseph Dunn
-
Publication number: 20080207601Abstract: Compositions for reducing dependency and addiction to substances of abuse are provided. Chloride channels such as the GABAA receptors are altered under conditions of dependency and withdrawal such that the electrophysiological properties of the GABAA receptor containing neurons are altered thereby providing a pathophysiological condition resulting in symptoms of dependency and withdrawal such as anxiety. Specifically, under conditions of withdrawal the relative ratio of the a1 receptor subunit decreases relative to the a4 receptor subunit. Endogenous neurosteroid production is also associated with the molecular changes underlying the alterations of GABA-gated chloride channels. Compositions of at least two compounds including at least one inhibitor of neurosteroid production are useful for treating the pathophysiology of addiction, dependency and substance abuse withdrawal.Type: ApplicationFiled: April 6, 2006Publication date: August 28, 2008Applicant: Hythiam , Inc.Inventor: Sanjay Sabnani
-
Publication number: 20080207599Abstract: The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and/or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and/or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.Type: ApplicationFiled: May 13, 2008Publication date: August 28, 2008Applicant: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez
-
Publication number: 20080132492Abstract: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.Type: ApplicationFiled: February 6, 2008Publication date: June 5, 2008Applicant: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez
-
Patent number: 7348321Abstract: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.Type: GrantFiled: July 15, 2003Date of Patent: March 25, 2008Assignee: Hythiam, Inc.Inventor: Juan Jose Legarda Ibañez
-
Patent number: 7186711Abstract: The invention relates to the use of flumazenil to produce a medicament for the treatment of cocaine dependency. The flumazenil can be administered sequentially in small quantities at short intervals until a therapeutically effective quantity for the treatment of cocaine dependency has been administered.Type: GrantFiled: July 15, 2003Date of Patent: March 6, 2007Assignee: Hythiam, Inc.Inventor: Juan Jose Legarda Ibañez
-
Publication number: 20060122219Abstract: The invention relates to the use of flumazenil to produce a medicament for the treatment of cocaine dependency. The flumazenil can be administered sequentially in small quantities at short intervals until a therapeutically effective quantity for the treatment of cocaine dependency has been administered.Type: ApplicationFiled: July 15, 2003Publication date: June 8, 2006Applicant: Hythiam, Inc.Inventor: Juan Legarda Ibanez
-
Publication number: 20040092509Abstract: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.Type: ApplicationFiled: July 15, 2003Publication date: May 13, 2004Applicant: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez